ArticleJournal of gastroenterology and hepatology2021

Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan.

Shintaro Sagami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.